The only Omicron sub-variant with its own name may become the next globally dominant strain of COVID-19.

The so-called Centaurus strain, which is scientifically known as BA.2.75, has quickly become India's dominant strain of COVID-19 in recent weeks and now accounts for roughly two-thirds of India's new cases, according to Shahid Jameel, a virologist at the University of Oxford. A Twitter user named Xabier Ostale gave BA.2.75 the unofficial name Centaurus in July, saying he named the strain after the galaxy, and it has taken off among some experts and media outlets.

This week, Chinese researchers published a new pre-print study on the strain suggesting that Centaurus "may prevail" as the globally dominant strain of COVID-19 following the current BA.4 and BA.5 wave. Centaurus's "growth advantage over BA.5 in India has become clearer" since the researchers looked at data nearly one month ago, one of the study's authors Yunlong Richard Cao, an assistant professor of biochemistry and immunology at Peking University, wrote on Twitter.

Centaurus does not appear to be driving a surge in hospitalizations or deaths in India. India has reported 49 COVID-related deaths per day in the last week, the same daily rate as two weeks ago, according to the New York Times.

The Chinese researchers wrote it "remains unclear" why the strain appeared more infectious in India than other strains. But they suggested a key mutation related to the virus's ability to bind to human cells may explain why Centaurus has displaced other subvariants in the country. India suffered a deadly wave of Delta infections in the summer of 2021, and Cao believes that because BA.5 shares a specific mutation with Delta, people in India may be better protected against BA.5 than people elsewhere, giving Centaurus room to flourish.

Centaurus also does not appear to be taking off in other countries.

In the U.S., BA.5 cases makes up 87.1% of all COVID infections, while other Omicron sub-strains BA.4 and BA.4.6 account for the second and third most cases at 6.6% and 4.8%, respectively, according to recently published data from the U.S. Centers for Disease Control. BA.2.75, meanwhile, has not registered enough cases to be officially listed in the U.S.'s data.